Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nino Aleksidze

Hematology & Oncology Montgomery, AL Medical Doctor

NPI 1427438530 CMS profile 1399870

4145 Carmichael Rd, Montgomery, AL 36106

Open in the dashboard

General payments

$4,845

231 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nino Aleksidze of Montgomery, AL is reported in the CMS Open Payments database as having received $4,845 across 231 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 59th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $643 31
2024 General $893 38
2023 General $937 50
2022 General $1,436 78
2021 General $436 7
2020 General $316 18
2019 General $183 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nino Aleksidze
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Nino Aleksidze were reported at $643. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Nino Aleksidze Hematology & Oncology median Middle half National median
2019 $183 $529 $121–$2,516 $163
2020 $316 $339 $82–$2,213 $114
2021 $436 $263 $49–$1,965 $132
2022 $1,436 $416 $103–$2,395 $149
2023 $937 $542 $125–$2,646 $160
2024 $893 $692 $141–$3,008 $164
2025 $643 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Celgene Corporation $642 32 payments
  2. E.R. Squibb & Sons, L.L.C. $428 27 payments
  3. Janssen Biotech, Inc. $407 18 payments
  4. Octapharma USA, Inc. $235 11 payments
  5. Novartis Pharmaceuticals Corporation $199 10 payments
  6. AbbVie, Inc. $163 7 payments
  7. Seattle Genetics, Inc. $160 5 payments
  8. Incyte Corporation $151 6 payments
  9. Genzyme Corporation $148 6 payments
  10. Merck Sharp & Dohme Corporation $139 9 payments
  11. Other $2,173 100 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,464 224 payments
  2. Education $381 7 payments
Products named General payments · program years 2019–2025
  1. OPDIVO $367 23 payments
  2. IMBRUVICA $250 10 payments
  3. REBLOZYL $197 11 payments
  4. Pomalyst $190 12 payments
  5. PANZYGA $155 7 payments
  6. Doptelet $135 4 payments
  7. DARZALEX $133 6 payments
  8. ENHERTU $126 3 payments
  9. ABECMA $125 1 payment
  10. VENCLEXTA $111 4 payments
  11. Other $3,180 163 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 50 drugs

Part D claims

1,617

Median for Hematology-Oncology: 604

Drug cost

$5,295,020

Median for Hematology-Oncology: $1,306,514

Branded share of claims

52.1%

Median for Hematology-Oncology: 31.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Calquence Acalabrutinib Maleate Brand 37 $555,923
Kisqali Ribociclib Succinate Brand 33 $516,093
Ibrance Palbociclib Brand 31 $449,374
Xtandi Enzalutamide Brand 30 $409,110
Neulasta Onpro Pegfilgrastim Brand 49 $387,001
Keytruda Pembrolizumab Brand 25 $317,390
Lupron Depot Leuprolide Acetate Brand 38 $313,759
Opdivo Nivolumab Brand 23 $307,045
Xgeva Denosumab Brand 87 $279,182
Nubeqa Darolutamide Brand 25 $278,644

The 10 drugs with the highest cost, of 50 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 88 billing codes

Paid by Medicare

$372,048

Of which drugs: $273,492

Medicare patients

173

Average age 73

Services billed

51,051

106 women, 67 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Diabetes 43%
Cancer 43%
Ischemic heart disease 39%
Chronic kidney disease 33%
Heart failure 28%
COPD 28%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 19 4,020 $75,048
Injection, ferric derisomaltose, 10 mg J1437 Office 11 1,300 $20,783
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 15 1,490 $132
Injection, diphenhydramine hcl, up to 50 mg J1200 Office 19 110 $70
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 18 71 $63
Injection, ondansetron hydrochloride, per 1 mg J2405 Office 11 536 $40

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REBLOZYL
  • Celgene Corporation $93
$93 — —
VENCLEXTA
  • AbbVie, Inc. $87
$87 — —
Hizentra
  • CSL Behring $69
$69 — —
LIBTAYO
  • Regeneron Healthcare Solutions, Inc. $61
$61 — —
ENHERTU
  • Daiichi Sankyo Inc. $55
$55 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

231 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record